Gary Moskowitz, DO
Internal Medicine · Syosset, NYNPI 1407852189
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 27.3% of the total. 2025 is the largest year on record at $1,115, 6.3 times the $178 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Novo Nordisk$578
- GSK$207
- Pfizer$190
- Lilly USA, LLC$173
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,607100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $1,533 |
| AstraZeneca | 59 | $1,259 |
| Novo Nordisk | 27 | $578 |
| GSK | 10 | $207 |
| Pfizer | 9 | $190 |
| Lilly USA, LLC | 9 | $173 |
| Merck | 8 | $151 |
| Amgen | 4 | $115 |
| Eisai Inc. | 6 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $110 |
| Boehringer Ingelheim | 5 | $107 |
| Otsuka America Pharmaceutical, Inc. | 5 | $105 |
| Phathom Pharmaceuticals, Inc. | 4 | $86 |
| Exact Sciences | 4 | $82 |
| Ardelyx, Inc. | 4 | $80 |
| Braintree Laboratories, Inc. | 4 | $74 |
| Verona Pharma, Inc. | 2 | $63 |
| Johnson & Johnson | 3 | $63 |
| Amarin Pharma, Inc. | 3 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Novartis | 3 | $55 |
| Evoke Pharma, Inc. | 2 | $52 |
| Redhill Biopharma Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $41 |
| Genentech USA, Inc. | 3 | $40 |
| Intercept Pharmaceuticals, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$244
How this compares
$5,607 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 89 | $85,711 |
| EliquisApixaban | 80 | $46,860 |
| JardianceEmpagliflozin | 30 | $38,895 |
| XareltoRivaroxaban | 43 | $28,045 |
| MounjaroTirzepatide | 20 | $23,379 |
| RybelsusSemaglutide | 11 | $22,497 |
| FarxigaDapagliflozin Propanediol | 22 | $22,223 |
| LinzessLinaclotide | 27 | $17,014 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,981 |
| TradjentaLinagliptin | 19 | $13,482 |
| Gvoke Hypopen 2-PackGlucagon | 17 | $10,262 |
| SantylCollagenase Clostridium Hist. | 20 | $9,328 |
| TrintellixVortioxetine Hydrobromide | 22 | $5,393 |
| SynthroidLevothyroxine Sodium | 60 | $5,166 |
| ErtapenemErtapenem Sodium | 11 | $4,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $151 | $85,71189 claims |
| Boehringer IngelheimJardiance, Tradjenta | $107 | $52,37749 claims |
| PfizerEliquis | $190 | $46,86080 claims |
| Johnson & JohnsonXarelto | $63 | $28,04543 claims |
| AbbVieLinzess, Synthroid, Lumigan | $1,533 | $26,46698 claims |
| Lilly USA, LLCMounjaro | $173 | $23,37920 claims |
| Novo NordiskRybelsus | $578 | $22,49711 claims |
| AstraZenecaFarxiga | $1,259 | $22,22322 claims |
| GSKTrelegy Ellipta | $207 | $14,98120 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $5,39322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Syosset
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.